The survival rate of liver cancer after radiotherapy for more than 2-3 years is 45.3% to 70%. Radiotherapy is divided into external radiotherapy and internal radiotherapy. External radiation therapy is to irradiate the tumor from outside the body by using rays (photons or particles) produced by radiotherapy equipment. Internal radiation therapy uses radionuclides, which are implanted into the tumor through body tubes or through needle channels. External radiation therapy is suitable for: early-stage patients who are unwilling or unable to undergo surgery, intermediate-stage patients who need postoperative adjuvant therapy, progressive or advanced-stage patients who are combined with oligometastases, and a portion of patients who are unable to undergo surgical resection but wish to have their tumors shrunk or downstaged by radiotherapy for conversion therapy. However, radiotherapy is usually combined with other treatments, such as TACE combined with radiotherapy and surgery combined with radiotherapy. Moreover, its prognosis is related to the patient’s condition (stage, etc.), the patient’s physical condition, and the response to the treatment, which varies from person to person. According to some studies, TACE combined with radiotherapy can significantly improve the prognosis of patients, and the 1-year survival rate of TACE group is 73.33%, which is significantly higher than that of TACE group (53.57%). Other studies have shown that the 1-year overall survival rate of patients treated with radiotherapy after surgery is about 80%, the 3-year overall survival rate is about 45%, and the 5-year overall survival rate is only about 20%. In conclusion, it is recommended that patients diagnosed with hepatocellular carcinoma should go to regular hospitals for evaluation of their condition and follow the doctor’s instructions for treatment to control disease progression and improve their prognosis.